RigiScan data under long-term testosterone therapy: improving long-term blood circulation of penile arteries, penile length and girth, erectile function, and nocturnal penile tumescence and duration
Canguven, O1; Talib, RA1; El Ansari, W1; Shamsodini, A1; Al Ansari, A1
1: Hamad Medical Corporation, Qatar
Objectives: Late-onset hypogonadism (LOH) presents with low serum testosterone (TT) levels and sexual and non-sexual symptoms. Erectile dysfunction affects a man's self-esteem and as a result partner relationship and quality of life. The aim of this study is to investigate the andrological clinical profile outcomes of testosterone therapy (TTh) in men (n=88) with symptomatic LOH complaints and symptoms. Erectile function was assessed using the International Index of Erectile Function-5 questionnaire at baseline and at 6 and 12 months of TRT. In addition, penile length was measured at baseline and 12 months. We also evaluated nocturnal penile tumescence (NPT, using RigiScan) and blood flow of cavernous arteries (penile Doppler ultrasonography) at baseline and 12 months of TT.
Material and Method(s): Eighty-eight LOH men (M age 51.1 years) with erectile dysfunction, all with serum TT <10.4 nmol/L before TRT. Patients received intramuscular long-acting testosterone undecanoate for 12 months.
Results: Following TRT, in all patients, serum TT levels were restored within 3 months to normal levels. Compared with baseline values, erectile function significantly improved at 6 (mean score increase 1.95) and 12 months (mean score increase 2.16). No significant changes in penile length were observed. NPT significantly improved at 12 months in terms of both the frequency (mean increase 1.27 times) and duration of rigidity (mean increase 5.12 minutes). As regards the blood flow of the cavernous arteries, we observed a significant improvement (decrease of 1.16 cm/sec) only in the end diastolic velocity of left cavernous artery.
Conclusion: TTh in men with LOH resulted in improvement of the erectile function, NPT and to some extent the blood flow of the cavernous arteries.
Work supported by industry: yes, by This study was supported by Hamad Medical Corporation Medical Research Center. (no industry support in study design or execution).Go Back